Impel NeuroPharma impelneuropharma.com


Public list: BIO 2016 (619) Pharma Startups (4733)

Impel is committed to improving the delivery of CNS therapeutics and is rapidly growing its pipeline of internal products through its INP-101, INP-102 and INP-104 programs. The Company's INP-104 product candidate is in late-stage development to improve the treatment of drug-resistant migraine in patients who have failed front-line triptan therapy. INP-101 is in clinical development to improve the management of pain in patients who have difficulty tolerating traditional systemically administered ...Show all

Impel is committed to improving the delivery of CNS therapeutics and is rapidly growing its pipeline of internal products through its INP-101, INP-102 and INP-104 programs. The Company's INP-104 product candidate is in late-stage development to impro...Show all

Company (Alive / Active)

Phone: 206-568-1466

Fax:

915 East Pine St.
Suite 401
Seattle, 98122
Washington, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Impel NeuroPharma $32.2M Dec 1, 2016
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Impel NeuroPharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors

Competitors

Company Status Description Investors

Chiasma

Newton, Massachusetts, United States
IPO / Went publicChiasma (NASDAQ: CHMA) is a biopharmaceutical company dedicated to improving the lives of patients with rare diseases by developing and commercializing oral medications that were previously available by injection only. The company's lead candidate is octreotide capsules, which has received orphan drug designation from the FDA and EMA. Chiasma is evaluating additional proteins, peptides and small molecule drugs that that are currently only available by injection but could potentially be converted...Show allLogin to see details

Critical Pharmaceuticals

Nottingham, England, United Kingdom
Alive / ActiveCritical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.Login to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Nozzles for nasal drug delivery Nov 08, 2013 Mar 20, 2018 Patent
Nasal drug delivery device Sep 03, 2013 Jan 24, 2017 Patent
Nozzles for nasal drug delivery Dec 15, 2017 Application
Nasal drug delivery device Oct 28, 2016 Application
Muroid family nasal device Oct 07, 2014 Application
See all 6 patents